Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 150

1.

Individual-level data on the relationships of progression-free survival, post-progression survival, and tumor response with overall survival in patients with advanced non-squamous non-small cell lung cancer.

Imai H, Takahashi T, Mori K, Ono A, Akamatsu H, Shukuya T, Taira T, Kenmotsu H, Naito T, Murakami H, Endo M, Nakajima T, Yamamoto N.

Neoplasma. 2014;61(2):233-40. doi: 10.4149/neo_2014_030.

PMID:
24299320
2.

Individual-level data on the relationships of progression-free survival and post-progression survival with overall survival in patients with advanced non-squamous non-small cell lung cancer patients who received second-line chemotherapy.

Imai H, Mori K, Ono A, Akamatsu H, Taira T, Kenmotsu H, Naito T, Kaira K, Murakami H, Endo M, Nakajima T, Takahashi T.

Med Oncol. 2014 Aug;31(8):88. doi: 10.1007/s12032-014-0088-3. Epub 2014 Jun 25.

PMID:
24961467
3.

Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancer.

Imai H, Mori K, Wakuda K, Ono A, Akamatsu H, Shukuya T, Taira T, Kenmotsu H, Naito T, Kaira K, Murakami H, Endo M, Nakajima T, Yamamoto N, Takahashi T.

Ann Thorac Med. 2015 Jan-Mar;10(1):61-6. doi: 10.4103/1817-1737.146885.

4.

Surrogate endpoints for overall survival in advanced non-small-cell lung cancer patients with mutations of the epidermal growth factor receptor gene.

Yoshino R, Imai H, Mori K, Takei K, Tomizawa M, Kaira K, Yoshii A, Tomizawa Y, Saito R, Yamada M.

Mol Clin Oncol. 2014 Sep;2(5):731-736. Epub 2014 Jul 1.

5.

Prognostic factors for second-line treatment of advanced non-small-cell lung cancer: retrospective analysis at a single institution.

Inal A, Kaplan MA, Kucukoner M, Urakci Z, Karakus A, Isikdogan A.

Asian Pac J Cancer Prev. 2012;13(4):1281-4.

6.

Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902.

Kim YH, Hirabayashi M, Togashi Y, Hirano K, Tomii K, Masago K, Kaneda T, Yoshimatsu H, Otsuka K, Mio T, Tomioka H, Suzuki Y, Mishima M.

Cancer Chemother Pharmacol. 2012 Aug;70(2):271-6. doi: 10.1007/s00280-012-1910-2. Epub 2012 Jun 30.

PMID:
22752216
7.

Postprogression survival in patients with advanced non-small-cell lung cancer who receive second-line or third-line chemotherapy.

Hayashi H, Okamoto I, Taguri M, Morita S, Nakagawa K.

Clin Lung Cancer. 2013 May;14(3):261-6. doi: 10.1016/j.cllc.2012.09.006. Epub 2012 Oct 27.

PMID:
23107465
8.
9.

Clinical impact of postprogression survival for overall survival in elderly patients (aged 75 years or older) with advanced nonsmall cell lung cancer.

Yoshino R, Imai H, Mori K, Tomizawa Y, Takei K, Tomizawa M, Kaira K, Yoshii A, Watanabe S, Saito R, Yamada M.

J Cancer Res Ther. 2015 Jul-Sep;11(3):606-11. doi: 10.4103/0973-1482.163683.

10.

Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer.

Hayashi H, Okamoto I, Morita S, Taguri M, Nakagawa K.

Ann Oncol. 2012 Jun;23(6):1537-41. doi: 10.1093/annonc/mdr487. Epub 2011 Oct 29. Review.

11.

Initial partial response and stable disease according to RECIST indicate similar survival for chemotherapeutical patients with advanced non-small cell lung cancer.

He L, Teng Y, Jin B, Zhao M, Yu P, Hu X, Zhang J, Li S, Gao Y, Liu Y.

BMC Cancer. 2010 Dec 14;10:681. doi: 10.1186/1471-2407-10-681.

12.

Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung cancer.

Ahn MJ, Yang JC, Liang J, Kang JH, Xiu Q, Chen YM, Blair JM, Peng G, Linn C, Orlando M.

Lung Cancer. 2012 Aug;77(2):346-52. doi: 10.1016/j.lungcan.2012.03.011. Epub 2012 Apr 23.

PMID:
22534669
13.

An indirect comparison of bevacizumab plus cisplatin-gemcitabine and cisplatin plus pemetrexed treatment for patients with advanced first-line non-squamous non-small cell lung cancer in East Asia.

Chang JW, Thongprasert S, Wright E, Tsang K, Kim HT, Ahn MJ, Kim JH, Kang JH, Kim SW, Walzer S.

Asia Pac J Clin Oncol. 2011 Jun;7 Suppl 2:13-21. doi: 10.1111/j.1743-7563.2011.01398.x.

PMID:
21585704
14.

A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer.

Schuette WH, Gröschel A, Sebastian M, Andreas S, Müller T, Schneller F, Guetz S, Eschbach C, Bohnet S, Leschinger MI, Reck M.

Clin Lung Cancer. 2013 May;14(3):215-23. doi: 10.1016/j.cllc.2012.10.001. Epub 2013 Jan 16.

PMID:
23332288
15.

Advanced non-small cell lung cancer (NSCLC): maintenance therapy for all?

Hashemi-Sadraei N, Pennell NA.

Curr Treat Options Oncol. 2012 Dec;13(4):478-90. doi: 10.1007/s11864-012-0209-1.

PMID:
22972369
16.

First-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer : analysis of the Italian patients enrolled in the SAiL study.

Bearz A, Passalacqua R, Alabiso O, Cinieri S, Gridelli C, Cravesana C, Crinò L.

Clin Drug Investig. 2012 Nov;32(11):755-60. doi: 10.1007/s40261-012-0001-9.

PMID:
23018280
17.

Pemetrexed and cisplatin for advanced non-squamous non-small cell lung cancer in Japanese patients: phase II study.

Kawano Y, Ohyanagi F, Yanagitani N, Kudo K, Horiike A, Tanimoto A, Nishizawa H, Ichikawa A, Sakatani T, Nakatomi K, Hagiwara S, Ninomiya H, Motoi N, Ishikawa Y, Horai T, Nishio M.

Anticancer Res. 2013 Aug;33(8):3327-33. Erratum in: Anticancer Res. 2013 Sep;33(9):4137.

PMID:
23898099
18.

Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data.

Rossi A, Di Maio M, Chiodini P, Rudd RM, Okamoto H, Skarlos DV, Früh M, Qian W, Tamura T, Samantas E, Shibata T, Perrone F, Gallo C, Gridelli C, Martelli O, Lee SM.

J Clin Oncol. 2012 May 10;30(14):1692-8. doi: 10.1200/JCO.2011.40.4905. Epub 2012 Apr 2. Review.

PMID:
22473169
19.

High response of second-line chemotherapy with pemetrexed or gemcitabine combined with carboplatin in patients with non-small-cell lung cancer experiencing progression following 6 months after concluding platinum-based chemotherapy.

Arrieta O, Villarreal-Garza C, Pachuca D, Michel Ortega RM, Martinez-Barrera L, Flores-Estrada D, Astorga A.

Med Oncol. 2011 Mar;28(1):300-6. doi: 10.1007/s12032-009-9401-y. Epub 2010 Jan 5.

PMID:
20049560
20.

Progression-free survival and post-progression survival in patients with advanced gastric cancer treated with first-line chemotherapy.

Shitara K, Matsuo K, Muro K, Doi T, Ohtsu A.

J Cancer Res Clin Oncol. 2013 Aug;139(8):1383-9. doi: 10.1007/s00432-013-1452-y. Epub 2013 May 25.

PMID:
23708301
Items per page

Supplemental Content

Write to the Help Desk